Search results
Results from the WOW.Com Content Network
German pharmaceutical and chemical company Merck KGaA will pay $280 million to settle a claim brought against a former subsidiary, Dey Pharma, regarding Medicare and Medicaid reimbursements, the U ...
The settlement could be valued at up to $12 billion, they said, which would make it the largest such settlement in U.S. pharmaceutical history. ... Merck agreed to pay nearly $5 billion to settle ...
The settlement amount includes both the civil (False Claims Act) settlement and criminal fine. Glaxo's $3 billion settlement included the largest civil False Claims Act settlement on record, [1] and Pfizer’s $2.3 billion ($3.5 billion in 2022) settlement including a record-breaking $1.3 billion criminal fine. [2]
In 2008, Merck settled most of its product-liability lawsuits for a total of $4.85 billion, and in 2016, Merck agreed to pay $830 million to settle a federal class-action lawsuit stemming from ...
By 2008 Glenmark was the fifth-biggest pharmaceutical company in India. [5] By 2011 the founder of the company was one of the richest men in India, [6] and Glenmark had worldwide sales of $778 million, a 37% increase over the last year's sales; the growth was driven by Glenmark's entry into the US and European generics markets. [7]
Reverse payment patent settlements, also known as "pay-for-delay" agreements, [1] are a type of agreement that has been used to settle pharmaceutical patent infringement litigation (or threatened litigation), in which the company that has brought the suit agrees to pay the company it sued. That is, the patent holder pays the alleged infringer ...
Members of the family who own OxyContin maker Purdue Pharma, and the company itself, agreed to pay up to $7.4 billion in a new settlement to lawsuits over the toll of the powerful prescription ...
Merck will make an initial payment of $625 million to Bristol and Japan's Ono. The company will also pay a 6.5-percent royalty rate on Keytruda sales from January 2017 to December 2023, and a 2.5-percent rate for the subsequent three years. [ 30 ]